

## SUPPLEMENTARY INFORMATION

### Peripheral proinflammatory Th1/Th17 immune cell shift is linked to disease severity in amyotrophic lateral sclerosis

**Authors:**

Mengmeng Jin<sup>1,2,#</sup>, Rene Günther<sup>1,3,#,\*</sup>, Katja Akgün<sup>1,2</sup>, Andreas Hermann<sup>+1,3-5</sup>, Tjalf Ziemssen<sup>+1,2</sup>

#Contribute equally as first author

+Contribute equally as senior author

\* corresponding author

Supplementary Tables:

Supplementary Table1: Correlation of immune cells to clinical parameters in ALS

Immune cells	ALSFRS-R score	ALSFRS-R slope	disease duration	ppFVC	Age	BMI
<b>CD3+ T cells</b>	r = -0.17 p = 0.188 N = 64	r = 0.23 p = 0.071 N = 64	r = -0.13 p = 0.312 N = 66	r = -0.04 p = 0.766 N = 61	r = 0.09 p = 0.449 N = 66	r = -0.14 p = 0.270 N = 65
<b>CD4+ T cells</b>	r = 0.07 p = 0.563 N = 64	r = 0.005 p = 0.966 N = 64	r = -0.10 p = 0.41 N = 66	r = 0.06 p = 0.638 N = 61	r = -0.14 p = 0.24 N = 66	r = 0.002 p = 0.987 N = 65
<b>CD8+T cells</b>	r = 0.07 p = 0.582 N = 64	r = -0.07 p = 0.567 N = 64	r = 0.02 p = 0.900 N = 66	r = 0.18 p = 0.161 N = 61	<b>r = -0.36</b> <b>p = 0.003</b> <b>N = 66</b>	r = 0.04 p = 0.759 N = 65
<b>CD4/CD8</b>	r = 0.04 p = 0.726 N = 64	r = 0.08 p = 0.518 N = 63	r = 0.08 p = 0.543 N = 64	r = -0.25 p = 0.062 N = 59	r = 0.14 p = 0.260 N = 66	r = -0.13 p = 0.312 N = 63
<b>Th1 cells</b>	<b>r = - 0.45</b> <b>p = 0.002</b> <b>N = 64</b>	<b>r = 0.29</b> <b>p = 0.021</b> <b>N = 64</b>	r = 0.16 p = 0.206 N = 66	<b>r = -0.26</b> <b>p = 0.045</b> <b>N = 61</b>	r = -0.21 p = 0.101 N = 66	r = 0.05 p = 0.708 N = 65
<b>Th2 cells</b>	r = 0.05 p = 0.722 N = 64	r = -0.03 p = 0.800 N = 64	r = 0.05 p = 0.690 N = 66	r = -0.12 p = 0.365 N = 61	r = -0.03 p = 0.820 N = 66	r = 0.02 p = 0.885 N = 65
<b>Th1/Th2</b>	r = -0.13 p = 0.291 N = 64	<b>r = 0.31</b> <b>p = 0.0114</b> <b>N = 64</b>	r = -0.16 p = 0.170 N = 63	r = -0.0045 p = 0.974 N = 57	r = -0.07 p = 0.581 N = 63	r = -0.04 p = 0.775 N = 62


<b>Treg cells</b>	r = -0.03 p = 0.802 N = 65	r = 0.02 p = 0.860 N = 65	r = -0.07 p = 0.600 N = 67	r = -0.01 p = 0.365 N = 62	r = -0.07 p = 0.600 N = 67	r = 0.07 p = 0.583 N = 66
<b>Th17 cells</b>	<b>r = -0.41</b> <b>p = 0.00089</b> <b>N = 64</b>	r = 0.06 p = 0.660 N = 64	<b>r = 0.34</b> <b>p = 0.006</b> <b>N = 66</b>	<b>r = -0.30</b> <b>p = 0.018</b> <b>N = 61</b>	r = -0.06 p = 0.605 N = 66	r = -0.12 p = 0.345 N = 65
<b>Treg/Th17</b>	<b>r = 0.29</b> <b>p = 0.020</b> <b>N = 64</b>	r = -0.10 p = 0.434 N = 64	r = -0.03 p = 0.785 N = 65	r = 0.22 p = 0.097 N = 61	r = -0.11 p = 0.390 N = 65	r = -0.02 p = 0.886 N = 64
<b>NK cells</b>	r = 0.09 p = 0.464 N = 64	r = -0.03 p = 0.800 N = 64	r = -0.05 p = 0.700 N = 66	r = -0.04 p = 0.745 N = 61	r = 0.00071 p = 1.000 N = 66	r = 0.06 p = 0.626 N = 65
<b>CD56<sup>bright</sup> CD16<sup>bright</sup> NK cells</b>	r = -0.02 p = 0.890 N = 64	r = -0.01 p = 0.965 N = 64	r = 0.03 p = 0.812 N = 66	r = 0.07 p = 0.588 N = 61	r = 0.06 p = 0.660 N = 66	r = -0.15 p = 0.249 N = 65
<b>CD56<sup>bright</sup> CD16<sup>dim</sup> NK cells</b>	r = 0.05 p = 0.720 N = 64	r = -0.13 p = 0.298 N = 64	r = 0.10 p = 0.422 N = 66	r = 0.13 p = 0.305 N = 61	r = -0.22 p = 0.072 N = 66	r = 0.11 p = 0.400 N = 65
<b>CD56<sup>bright</sup> CD16<sup>-</sup> NK cells</b>	r = 0.02 p = 0.900 N = 64	r = -0.09 p = 0.465 N = 64	r = 0.12 p = 0.333 N = 66	r = 0.09 p = 0.504 N = 61	r = -0.16 p = 0.189 N = 66	r = 0.01 p = 0.960 N = 65
<b>CD56<sup>dim</sup> CD16<sup>dim</sup> NK cells</b>	r = 0.07 p = 0.607 N = 64	r = 0.09 p = 0.472 N = 64	r = -0.17 p = 0.173 N = 66	r = -0.05 p = 0.703 N = 61	r = -0.08 p = 0.500 N = 66	r = 0.09 p = 0.498 N = 65
<b>CD56<sup>dim</sup> CD16<sup>bright</sup> NK cells</b>	r = -0.01 p = 0.925 N = 64	r = 0.05 p = 0.705 N = 64	r = -0.06 p = 0.650 N = 66	r = -0.12 p = 0.379 N = 61	<b>r = 0.39</b> <b>p = 0.001</b> <b>N = 66</b>	r = -0.12 p = 0.346 N = 65

<b>NKT cells</b>	r = 0.14 p = 0.263 N = 64	r = 0.002 p = 0.987 N = 64	r = -0.18 p = 0.141 N = 66	r = 0.07 p = 0.612 N = 61	r = -0.18 p = 0.143 N = 66	r = 0.09 p = 0.497 N = 65
<b>CD4+NKT cells</b>	r = -0.05 p = 0.691 N = 64	r = 0.02 p = 0.893 N = 64	r = -0.04 p = 0.776 N = 66	r = -0.02 p = 0.890 N = 61	r = 0.02 p = 0.842 N = 66	r = -0.11 p = 0.387 N = 65
<b>CD8+NKT cells</b>	r = 0.01 p = 0.938 N = 64	r = 0.06 p = 0.628 N = 64	r = -0.16 p = 0.194 N = 66	r = -0.15 p = 0.256 N = 61	r = -0.07 p = 0.590 N = 66	r = -0.03 p = 0.801 N = 65
<b>CD14+Mo</b>	r = 0.14 p = 0.287 N = 63	r = -0.11 p = 0.403 N = 63	r = -0.13 p = 0.322 N = 65	r = 0.02 p = 0.868 N = 60	r = -0.14 p = 0.260 N = 65	r = -0.05 p = 0.711 N = 65
<b>Classical Mo</b>	r = 0.15 p = 0.256 N = 63	r = -0.01 p = 0.920 N = 63	r = -0.05 p = 0.670 N = 65	r = 0.03 p = 0.827 N = 60	r = 0.03 p = 0.810 N = 65	r = -0.02 p = 0.895 N = 64
<b>Intermediate Mo</b>	r = -0.01 p = 0.928 N = 63	r = -0.02 p = 0.890 N = 63	r = 0.04 p = 0.750 N = 65	r = 0.07 p = 0.582 N = 60	r = -0.04 p = 0.760 N = 65	r = -0.04 p = 0.744 N = 64
<b>Non-classical Mo</b>	r = -0.04 p = 0.762 N = 63	r = -0.07 p = 0.590 N = 63	r = -0.0024 p = 0.900 N = 65	r = 0.09 p = 0.496 N = 60	r = -0.05 p = 0.700 N = 65	r = 0.10 p = 0.443 N = 64

**Supplementary Table 2: Correlation between cytokines in serum and clinical parameters in ALS**

<b>Cytokines in the Serum</b>	<b>ALSFRS-R score</b>	<b>ALSFRS-R slope</b>	<b>disease duration</b>	<b>ppFVC</b>	<b>Age</b>	<b>BMI</b>
<b>IL-6</b>	r = 0.11 p = 0.349 N = 71	r = -0.13 p = 0.272 N = 70	<b>r = 0.52</b> <b>p &lt; 0.0001</b> <b>N = 71</b>	r = 0.03 p = 0.821 N = 65	r = 0.07 p = 0.550 N = 71	r = 0.03 p = 0.789 N = 70
<b>IL-1beta</b>	r = -0.03 p = 0.79 N = 71	<b>r = 0.35</b> <b>p = 0.004</b> <b>N = 70</b>	r = 0.03 p = 0.831 N = 71	r = -0.16 p = 0.205 N = 65	r = -0.13 p = 0.278 N = 71	r = -0.01 p = 0.3 N = 70
<b>IFN-gamma</b>	r = 0.086 p = 0.476 N = 71	r = -0.0492 p = 0.686 N = 70	r = 0.16 p = 0.184 N = 71	r = -0.10 p = 0.446 N = 65	r = 0.003 p = 0.980 N = 71	r = -0.10 p = 0.417 N = 70


## Supplementary Figures



### Supplementary Figure 1 Peripheral B cell profiles in ALS patients and healthy controls.


Depicted are relative counts of CD19+ B cells (A), naïve B cells (B), memory B cells (C) and B regulatory cells (D) of ALS versus controls as well as relative counts of CD19+ B cells (E), naïve B cells (F), memory B cells (G) and B regulatory cells (H) of fast ALS versus slow ALS. Results are presented as raw data, each circle represents one healthy control and each quad represents one ALS patient, horizontal lines indicate mean values.

\* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




**Supplementary Figure 2 Peripheral DC subsets in ALS patients and healthy controls.**

Depicted are relative counts of slanDCs (A), BDCA1+DCs (B), BDCA2+DCs (C), BDCA3+DCs (D) and BDCA4+DCs (E) of ALS versus controls as well as relative counts of SlanDCs (F), BDCA1+DCs (G), BDCA2+DCs (H), BDCA3+DCs (I) and BDCA4+DCs (J) of fast ALS versus slow ALS. Results are presented as raw data, each circle represents one healthy control and each quad represents one ALS patient, horizontal lines indicate mean values. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .




**Supplementary Figure 3 Peripheral T cell and B cell subsets in comparison of fast versus slow ALS.** Depicted are relative counts of CD3+T cells (A), CD4+T cells (B), CD8+T cells (C), ratio of CD4+/CD8+T cells (D), Th1 cells (E), Th2 cells (F), ratio of Th1/Th2 cells (G), Th17 cells (H) and Treg cells (I) and the ratio of Treg/Th17 cells (J) of fast ALS versus slow ALS. Results are presented as raw data, each circle represents one healthy control and each quad represents one ALS patient, horizontal lines indicate mean values. \* $p < 0.05$ , \*\* $p < 0.01$ , \*\*\* $p < 0.001$ .






**Supplementary Figure 4 Peripheral NK cells and Mo subset of fast versus slow ALS.** Depicted are relative counts of NK cells (A), CD56<sup>bright</sup>CD16<sup>bright</sup>NK cells (B), CD56<sup>bright</sup>CD16<sup>dim</sup>NK cells (C), CD56<sup>bright</sup>CD16<sup>-</sup>NK cells (D), CD56<sup>dim</sup>CD16<sup>bright</sup>NK cells (E), CD56<sup>dim</sup>CD16<sup>dim</sup>NK cells (F), NKT cells (G), CD4+NKT cells (H), CD8+NKT cells (I), CD14+Mo (J), classical Mo cells (K), intermediate Mo cells (L), and non-classical Mo cells (M) of fast versus slow ALS. Results are presented as raw data, each circle represents one healthy control and each quad represents one ALS patient, horizontal lines indicate mean values. \*p < 0.05, \*\*p < 0.01, \*\*\*p < 0.001.



**Supplementary Figure 5 Cytokines in the blood serum of fast versus slow ALS.** Levels of IL-1beta (A), IL-6 (B), TNF-alpha (C), IL-10 (D), IL-12 (E), IL-23 (F), IFN-gamma (G) and IL-17A (H) in the serum of fast ALS and slow ALS were calculated as fold change over the mean of healthy controls. Data are depicted as histograms (means  $\pm$  SD). \*p < 0.05.



**Supplementary Figure 6 Representative Facs plots of Tcells, Th1, Th17 and Treg cells in ALS patients and healthy controls.**